WASHINGTON, DC – In the wake of today’s U.S. Supreme Court decision in the United States v. Arthrex Inc. case, the Coalition Against Patent Abuse (CAPA) said that it’s critical for Congress to now address this decision and work to protect and strengthen the Inter Partes Review (IPR) within the U.S. Patent & Trademark Office (USPTO), by ensuring […]

Continue Reading

WHAT YOU NEED TO KNOW Have You Heard? The Coalition Against Patent Abuse (CAPA) is Fighting Against Anti-Competitive Tactics Used by Some Major Pharmaceutical Companies to Keep Competition Out, Prices High. In a mini-series called, “Spot-On Savings,” CAPA outlined how the U.S. Patent and Trademark Office (USPTO), through its inter partes review (IPR) process, can generate […]

Continue Reading

WHAT YOU NEED TO KNOW Recently, Matrix Global Advisors (MGA) released a white paper that highlights how patent thickets increase barriers for American patients to access affordable biosimilar medications and treatments.   “It is no secret that many pharmaceutical companies today utilize loopholes within the patent system to extend their monopolies while expanding their profits. This white […]

Continue Reading